BISPECIFIC ANTIBODIES IN RELAPSED REFRACTORY MULTIPLE MYELOMA: A SYSTEMATIC REVIEW OF EFFICACY AND SAFETY IN PHASE I/II/III CLINICAL TRIAL

Main Article Content

Syed Ahsan Ali Shah
Dr. Vanessa Owiredu
Abhijeet Kumar
Amgad Samir Abdelmageed Mohamed Elfeki
Ahmed Samir Abdelmageed Mohamed Elfiki
Faryal Tariq
Zacarius William Seit
Shams Almallah
Mohammad Alhajri

Keywords

bispecific antibodies, multiple myeloma, clinical trials, relapsed refractory, immunosuppressive microenvironment

Abstract

This study comprehensively evaluates the efficacy and safety of bispecific antibodies (BiAbs). While in the treatment of relapsed refractory, multiple myeloma (RRMM) through an analysis of clinical trials of Phase I, Phase II, and Phase III. Despite significant progress with established therapies, the challenges of RRMM persist. Also, it necessitates innovative approaches. BiAbs, with their unique capacity to engage dual antigens, show promise in overcoming the complexities of MM. Moreover, it also overcomes immunosuppressive microenvironment. The current study elucidates the key mechanisms of action, including T-cell activation. It covers the induction of tumor cell apoptosis, highlighting the transformative potential of BiAbs. While comparing with established therapies, such as chimeric antigen receptor (CAR)-T cell therapies and anti-CD38 monoclonal antibodies. That situates BiAbs within the evolving MM treatment landscape. Thud encourages outcomes from ongoing trials demonstrate deep responses with a favorable safety profile. And its positioning BiAbs as a pivotal addition to RRMM therapeutics. Hence, the synthesis of Phase I-III trial findings provides valuable insights, guiding future research towards optimizing efficacy and safety. it ultimately enhances patient outcomes in the challenging realm of relapsed refractory multiple myeloma.

Abstract 225 | Pdf Downloads 39

References

1. Alsajjan, R., & Mason, W. P. (2023). Bispecific T-cell engagers and chimeric antigen receptor T-cell therapies in glioblastoma: an update. Current Oncology, 30(9), 8501-8549.
2. Bhatt, P., Kloock, C., & Comenzo, R. (2023). Relapsed/refractory multiple myeloma: A review of available therapies and clinical scenarios encountered in myeloma relapse. Current Oncology, 30(2), 2322-2347.
3. Chacon, A., Leleu, X., & Bobin, A. (2023). 30 Years of Improved Survival in Non-Transplant-Eligible Newly Diagnosed Multiple Myeloma. Cancers, 15(7), 1929.
4. Culp, P. A., Degenhardt, J. D., Dettling, D. E., & May, C. (2022). T-cell engaging bispecific antibody therapy. In Cancer Immunology and Immunotherapy (pp. 267-319). Elsevier.
5. Dima, D., Jiang, D., Singh, D. J., Hasipek, M., Shah, H. S., Ullah, F., Khouri, J., Maciejewski, J. P., & Jha, B. K. (2022). Multiple myeloma therapy: emerging trends and challenges. Cancers, 14(17), 4082.
6. Foulk, B., Schaffer, M., Gross, S., Rao, C., Smirnov, D., Connelly, M. C., Chaturvedi, S., Reddy, M., Brittingham, G., & Mata, M. (2018). Enumeration and characterization of circulating multiple myeloma cells in patients with plasma cell disorders. British Journal of Haematology, 180(1), 71-81.
7. Gandolfi, S., Laubach, J. P., Hideshima, T., Chauhan, D., Anderson, K. C., & Richardson, P. G. (2017). The proteasome and proteasome inhibitors in multiple myeloma. Cancer and Metastasis Reviews, 36, 561-584.
8. Krejcik, J., Barnkob, M. B., Nyvold, C. G., Larsen, T. S., Barington, T., & Abildgaard, N. (2021). Harnessing the immune system to fight multiple myeloma. Cancers, 13(18), 4546.
9. Lum, L. G., & Al-Kadhimi, Z. (2008). Development and prospects for bispecific antibody-based therapeutics in cancer and other applications. Expert Opinion on Drug Discovery, 3(9), 1081-1097.
10. Neumeister, P., Schulz, E., Pansy, K., Szmyra, M., & Deutsch, A. J. (2022). Targeting the microenvironment for treating multiple myeloma. International Journal of Molecular Sciences, 23(14), 7627.
11. Rotolo, A., Karadimitris, A., & Ruella, M. (2018). Building upon the success of CART19: chimeric antigen receptor T cells for hematologic malignancies. Leukemia & lymphoma, 59(9), 2040-2055.
12. Ruhela, V., Oberoi, R., Gupta, A., & Gupta, R. (2023). A Comprehensive Targeted Panel of 282 Genes: Unveiling Key Biomarkers in Multiple Myeloma. bioRxiv, 2023.2010. 2028.564536.
13. Solimando, A. G., Vacca, A., & Ribatti, D. (2020). A comprehensive biological and clinical perspective can drive a patient-tailored approach to multiple myeloma: Bridging the gaps between the plasma cell and the neoplastic niche. Journal of Oncology, 2020.

Most read articles by the same author(s)